Nathan J Brendish
Overview
Explore the profile of Nathan J Brendish including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dedeoglu B, Tanner A, Brendish N, Moyses H, Clark T
J Infect
. 2024 Nov;
89(6):106360.
PMID: 39581271
Objectives: Distinguishing bacterial from viral acute respiratory infection (ARI) is challenging, leading to inappropriate antimicrobial use and antimicrobial resistance. We evaluated the accuracy of two host-response tests to differentiate bacterial...
2.
Chapman M, Brendish N, Morris M, Spalluto C, McCormick C, Moyses H, et al.
J Infect
. 2024 Sep;
89(5):106264.
PMID: 39244102
Background: A novel single-use, analyser-free, molecular point-of-care test for SARS-CoV-2 (Veros COVID-19 test, Sherlock Biosciences) could reduce time to results and improve patient care and flow in the emergency department...
3.
Schober T, Wong K, DeLisle G, Caya C, Brendish N, Clark T, et al.
JAMA Intern Med
. 2024 Mar;
184(5):528-536.
PMID: 38436951
Importance: Rapid tests for respiratory viruses, including multiplex panels, are increasingly available in emergency departments (EDs). Their association with patient outcomes remains unclear. Objective: To determine if ED rapid respiratory...
4.
Brendish N, Davis C, Chapman M, Borca F, Waddington D, Hill C, et al.
J Infect
. 2023 Nov;
88(1):41-47.
PMID: 37977337
Objectives: FebriDx is a CE-marked, FDA-approved point-of-care test that detects the antiviral host response protein Myxovirus Resistance Protein A (MxA), in addition to C-reactive protein, using finger-prick blood. FebriDx MxA...
5.
Brendish N, Beard K, Malachira A, Tanner A, Sanga-Nyirongo L, Gwiggner M, et al.
Lancet Infect Dis
. 2023 Apr;
23(8):945-955.
PMID: 37116527
Background: Single-occupancy isolation rooms are a finite resource in UK hospitals but are crucial in preventing transmission of infection. Patients with suspected gastroenteritis are nursed in single-occupancy rooms, but delays...
6.
Penrice-Randal R, Dong X, Shapanis A, Gardner A, Harding N, Legebeke J, et al.
Front Immunol
. 2022 Oct;
13:988685.
PMID: 36203591
Background: The COVID-19 pandemic has created pressure on healthcare systems worldwide. Tools that can stratify individuals according to prognosis could allow for more efficient allocation of healthcare resources and thus...
7.
Legebeke J, Lord J, Penrice-Randal R, Vallejo A, Poole S, Brendish N, et al.
Front Immunol
. 2022 Jun;
13:853265.
PMID: 35663963
The worldwide COVID-19 pandemic has claimed millions of lives and has had a profound effect on global life. Understanding the body's immune response to SARS-CoV-2 infection is crucial in improving...
8.
Brendish N, Tanner A, Poole S, Beard K, Naidu V, Mansbridge C, et al.
Infect Dis Ther
. 2022 May;
11(3):1267-1280.
PMID: 35534764
Introduction: RT-PCR has suboptimal sensitivity for the diagnosis of COVID-19. A composite reference standard comprising RT-PCR plus radiological and clinical features has been recommended for diagnostic accuracy studies. The FebriDx...
9.
Mansbridge C, Tanner A, Beard K, Borca F, Phan H, Brendish N, et al.
Infect Control Hosp Epidemiol
. 2022 Apr;
43(8):1099.
PMID: 35403585
No abstract available.
10.
Livingstone R, Lin H, Brendish N, Poole S, Tanner A, Borca F, et al.
J Infect
. 2022 Feb;
84(4):558-565.
PMID: 35108599
Objectives: Risk of hospital-acquired COVID-19 (HA-COVID-19) infection is increased by cohorting infected and non-infected patients together in assessment areas, whist awaiting laboratory PCR results. Molecular point-of-care tests (mPOCT) reduce time...